SCHEMBL5462663

SCHEMBL5462663

O=C(O)c1ccc(NC(=O)c2c[c]ccc2O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ MITF O75030 1/20 0.47
▸ FFAR1 O14842 1/20 0.46
▸ LMNA P02545 3/20 0.46
▸ TP53 P04637 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ POLB P06746 2/20 0.45
▸ F2 P00734 1/20 0.44
▸ F10 P00742 1/20 0.44
▸ PLG P00747 1/20 0.44
▸ PLAU P00749 1/20 0.44
▸ PLAT P00750 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ ALOX15 P16050 1/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469832 0.86 LMNA (0.60) MEN1KMT2ALMNATP53HSD17B10
SCHEMBL5463771 0.84 RAB9A (0.51) MEN1KMT2ALMNATP53HSD17B10
SCHEMBL5468746 0.83 MEN1 (0.54) MEN1KMT2AMITFTP53HTT
SCHEMBL5462330 0.81 PNLIP (0.62) MEN1KMT2ALMNATP53POLB
SCHEMBL5468300 0.80 SNCA (0.56) MEN1KMT2AALOX15NPC1RAB9A
SCHEMBL5464092 0.78 TOP1 (0.46) MEN1KMT2ALMNATP53HSD17B10
SCHEMBL8194070 0.78 MEN1 (0.77) MEN1KMT2AFFAR1LMNATP53
SCHEMBL5463888 0.77 PTGS1 (0.56) MEN1KMT2ALMNAKDM4EPOLB
SCHEMBL5455155 0.77 MEN1 (0.40) MEN1KMT2ALMNATP53HSD17B10
SCHEMBL11163149 0.75 P2RX1 (0.56) MEN1KMT2AMITFFFAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 MEN1 2892/4885KMT2A 2948/4885MITF 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback